ScreenerHero

IDYA IDEAYA Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · ideayabio.com
36.26USD-1.01%Mkt Cap: 3.50B $P/E: —

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.50B USD
Enterprise Value2.73B USD
Revenue (TTM)234.13M USD
Gross Profit-139.88M USD
Net Income (TTM)-113.70M USD
Revenue/Share2.62 USD
Last Price36.26 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.14
PEG—
EV/EBITDA-12.77
EV/Revenue11.68
P/S15.10
P/B2.94
EPS (TTM)-1.86
EPS (Forward)-4.01
52W Range
25.3664% of range42.33
52W High42.33 USD
52W Low25.36 USD
Profitability
Gross Margin-59.75%
Oper. Margin-1380.73%
EBITDA Margin-91.49%
Profit Margin-51.99%
ROE-11.11%
ROA-10.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.10M USD
CapEx (TTM)2.37M USD
FCF Margin-30.26%
FCF Yield-2.02%
Net Debt-799.65M USD
Net Debt/EBITDA3.73
Balance Sheet
Debt/Equity0.03
Current Ratio10.45
Quick Ratio10.21
Book Value/Sh12.44 USD
Cash/Share8.59 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.75 USD
Upside (mean)+45.5%
Target Range31.00 USD – 65.00 USD
31.00+45.5% to mean65.00
# Analysts12
Ownership
Shares Out.96.49M
Float90.63M
Insiders2.19%
Institutions107.70%
Short Interest
Short Ratio13.8d
Short % Float11.96%
Short % Out.10.29%
Shares Short9.93M
Short (prev mo.)10.40M
Technical
SMA 5038.06 (-4.7%)
SMA 20034.09 (+6.4%)
Beta-0.04
S&P 52W Chg16.45%
Avg Vol (30d)795.27K
Avg Vol (10d)957.97K
Technical Indicators
RSI (14)42.0
MACD-0.2245
MACD Signal0.0012
MACD Hist.-0.2257
BB Upper39.52 USD
BB Middle37.82 USD
BB Lower36.12 USD
BB Width9.01%
ATR (14)1.497 USD
Vol Ratio (20d)0.65x